Viral Antigens
Viral Antigens(病毒抗原)
A viral Antigen is an antigen with multiple antigenicities that is protein in nature, strain-specific, and closely associated with the virus particle. A viral antigen is a protein encoded by the viral genome.A viral protein is an antigen specified by the viral genome that can be detected by a specific immunological response.
Viruses are infectious pathogens that cause serious diseases & major threats for global public health, such as influenza, hepatitis, & AIDS. Virus is a sub-micrometer particle that has DNA or RNA packed in a shell called capsid. Viral antigens protrude from the capsid and often fulfill important function in docking to the host cell, fusion, and injection of viral DNA/RNA. Antibody-based immune responses form a first layer of protection of the host from viral infection; however, in many cases a vigorous cellular immune response mediated by T-cells and NK-cells is required for effective viral clearance. When cellular immunity is unable to clear the virus, the infection can become chronic, and serum antibodies to the viral pathogen are used as first indicator for the diagnosis of the disease.
ELISAs provide a valuable tool in the detection and diagnosis of virus infection. The ability to produce recombinant viral proteins will ensure that future ELISAs are safe, specific and rapid. Even when a virus cannot be cultured, provided gene sequence is available, it is possible to rapidly respond to emerging viruses and new viral strains of existing pathogens.
Recombinant viral antigens contain part of viral sequence meaning that the recombinant antigen contains a region which can be recognized by different antibodies produced by different individuals. This reduces the risk of false negatives which can occur with synthetic peptides, which contain only a small portion of the entire protein. If an individual infected with a viral antigen makes antibodies to a part of the protein not included in the synthetic peptides, a false negative results.
Recombinant viral protein usually contains a fusion protein/partner which produces superior attachment to assay surfaces such as wells. For this reason, smaller amounts of recombinant protein will produce the same results as larger amounts of unfused protein. The choice of fusion partner prevents false positives, allowing superior adhesion without incorrect results.
Recombinant Viral proteins are expressed in bacteria, yeast, mammalian cells, and viruses. E. Coli cells were first to be used for this purpose but the expressed proteins were not glycosylated, which was a major drawback since many of the immunogenic proteins of viruses such as the envelope glycoproteins, were glycosylated. Nevertheless, in many instances, it was demonstrated that the non-glycosylated protein backbone was just as immunogenic. The obvious advantage of recombinant viral antigens is that they are available in unlimited quantities and the production and quality control processes is simple.
Advantages of defined using recombinant viral antigens:
1. Production and quality control is simple.
2. No nucleic acids or other viral or external proteins, therefore less toxic.
3. Safer in cases where viruses are oncogenic or establish a persistent infection.
4. Feasible even if virus cannot be cultivated
Disadvantages:
1. May be less immunogenic than conventional inactivated whole-virus vaccines.
2. Requires adjuvant .
3. Fails to elicit CMI.
Facts about Viral Antigens:
1. A Viral Protein Mimics its Way into cells.
2. Viral Protein Helps Infected T Cells Stick To Uninfected Cells.
3. The Viral Protein A238L Inhibits Cyclooxygenase-2 Expression through a Nuclear Factor of Activated T Cell-dependent Trans-activation Pathway.
4. Viral Protein is an effective preventative against ear infection.
5. HIV-1 Viral Protein R Induces Apoptosis via a Direct Effect on the Mitochondrial Permeability Transition Pore.
6. The Level of Viral Antigen Presented by Hepatocytes Influences CD8 T-Cell Function.
7. Antigen-presenting cells from calves persistently infected with bovine viral diarrhea virus, a member of the Flaviviridae, are not compromised in their ability to present viral antigen.
8. There is a difference in the distribution and spread of a viral antigen, development of lesions and correlation between presence of viral antigen and lesions.
9. The absence of viral antigens on the surface of equine herpesvirus-1-infected peripheral blood mononuclear cells is a strategy to avoid complement-mediated lysis.
10. Viral Protein Influences Key Cell-signaling Pathway.
11. A viral protein produced by cancer-causing virus influences a key signaling pathway in the immune cells that the virus infects. This stimulates the cells to divide, helping the virus spread through the body.
12. Protection by recombinant viral proteins against a respiratory virulent avian metapneumovirus has been achieved.
13. Viral O-acetylesterases are found in influenza C viruses and Corona-viruses. Viral O-acetylesterases remove cellular receptors from the surface of target cells which destroys the receptor. Recombinant viral O-acetylesterases derived from Sf9 insect cells as chimeric proteins fused to eGFP specifically hydrolyze 9-O-acetylated sialic acids, while that of sialodacryoadenitis virus, a rat coronavirus related to mouse hepatitis virus, is specific for 4-O-acetylated sialic acid. The recombinant esterases were shown to specifically de-O-acetylate sialic acids on glycoconjugates. The recombinant viral proteins can be used to unambiguously identify O-acetylated acids.
- Borrelia(28)
- Chagas(3)
- Chikungunya(7)
- Chlamydia(10)
- Cytomegalo(8)
- Dengue(50)
- Ebola(4)
- EBV(13)
- Encephalitis(8)
- Feline Leukemia Virus(1)
- Hantavirus(1)
- HBsAg(8)
- Helicobacter Pylori(3)
- Hepatitis A(15)
- Hepatitis B(10)
- Hepatitis C(85)
- Hepatitis D(1)
- Hepatitis E(5)
- Herpes(11)
- HERV-K(1)
- HIV(152)
- HTLV(6)
- Influenza(73)
- Lassa(2)
- Malaria(77)
- Mumps(1)
- Mycoplasma(4)
- Norovirus(4)
- Papillomavirus(5)
- Parvovirus(3)
- Rubella(3)
- S. Typhi(5)
- SARS(85)
- Shiga Like Toxin(2)
- Toxoplasma(9)
- Treponema(16)
- Varicella(3)
- West Nile(2)
- Zika(14)
Viral Antigens 相关产品(718)
- GC70780Ingenol-3-palmitateCAS: 52557-26-3纯度: >99.00%
Ingenol-3-palmitate是一种天然产物,可以从Euphorbia ebracteolata的根中分离出来。
- GC70929Fipravirimat dihydrochlorideCAS: 2442512-14-1纯度: 不显示
Fipravirimat dihydrochloride是一种有效的HIV-1抑制剂。
- GC72333ZinlirvimabCAS: 2417213-75-1纯度: 不显示
Zinlirvimab是一种针对HIV-1 gp120包膜糖蛋白(IIIB gp120 V3环)的人IgG1-λ2 HIV中和抗体。
- GC73003EBNA1-IN-SC7CAS: 324022-08-4纯度: >99.00%
EBNA1-IN-SC7(化合物SC7)是一种选择性EBNA1 (Epstein-Barr nuclear antigen 1)抑制剂,干扰EBNA1- dna结合活性,IC50值为23 μM。
- GC73260EBV lytic cycle inducer-1CAS: 394668-43-0纯度: >98.00%
Epstein-Barr病毒EBV lytic cycle inducer-1 Dp44mT化合物C7是一种铁螯合物样化合物。
- GC73805Antiviral agent 55CAS: 371137-60-9纯度: >90.00%
Antiviral agent 55(化合物95)是人类免疫缺陷病毒1和2 (HIV 1和HIV 2)的抑制剂,具有抗病毒活性。
- GC74067HIV-1 inhibitor-69CAS: 257891-65-9纯度: >99.00%
HIV-1 inhibitor-69 (compound Test set 1)是一种HIV-1 RT抑制剂。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC70780 | Ingenol-3-palmitate | 52557-26-3 | >99.00% | |
Ingenol-3-palmitate是一种天然产物,可以从Euphorbia ebracteolata的根中分离出来。 | ||||
| GC70800 | EFdA-TP tetrasodium | 2883783-00-2 | 不显示 | |
EFdA-TP tetrasodium是一种强效的核苷逆转录酶(RT)抑制剂。 | ||||
| GC70929 | Fipravirimat dihydrochloride | 2442512-14-1 | 不显示 | |
Fipravirimat dihydrochloride是一种有效的HIV-1抑制剂。 | ||||
| GC71227 | PYR01 | 2560576-15-8 | >98.00% | |
PYR01是一种有效的HIV-1非核苷逆转录酶抑制剂。 | ||||
| GC71244 | UC-781 | 178870-32-1 | 不显示 | |
UC-781 (NSC 675186)是一种高效、选择性的HIV-1非核苷逆转录酶抑制剂(NNRTI), IC50值为5 nM。 | ||||
| GC71952 | Interiorin | 119139-55-8 | 不显示 | |
Interiorin可以从南五味子中分离出来,具有中等的抗HIV活性,EC50值为1.6 lg/mL。 | ||||
| GC71981 | Gomisin M1 | 82467-50-3 | >99.00% | |
Gomisin M1((±)-Gomisin M1)是一种有效的抗HIV药物,EC50<0.65μM。 | ||||
| GC72038 | Icariside D2 | 38954-02-8 | >98.00% | |
Icariside D2从番荔枝果实中分离出来的,抑制血管紧张素转换酶。 | ||||
| GC72333 | Zinlirvimab | 2417213-75-1 | 不显示 | |
Zinlirvimab是一种针对HIV-1 gp120包膜糖蛋白(IIIB gp120 V3环)的人IgG1-λ2 HIV中和抗体。 | ||||
| GC72470 | Elipovimab | 2101210-43-7 | >97.00% | |
Elipovimab是一种有效的广泛中和HIV-1抗体,用于靶向消除hiv感染细胞。 | ||||
| GC72835 | NSC260594 | 906718-66-9 | >96.00% | |
NSC260594诱导细胞凋亡。 | ||||
| GC72952 | 1E7-03 | 1565845-92-2 | >95.00% | |
1E7-03是一种靶向蛋白磷酸酶-1的低分子量四喹啉衍生物,可以抑制HIV-1的转录。 | ||||
| GC73003 | EBNA1-IN-SC7 | 324022-08-4 | >99.00% | |
EBNA1-IN-SC7(化合物SC7)是一种选择性EBNA1 (Epstein-Barr nuclear antigen 1)抑制剂,干扰EBNA1- dna结合活性,IC50值为23 μM。 | ||||
| GC73260 | EBV lytic cycle inducer-1 | 394668-43-0 | >98.00% | |
Epstein-Barr病毒EBV lytic cycle inducer-1 Dp44mT化合物C7是一种铁螯合物样化合物。 | ||||
| GC73284 | Trecovirsen sodium | - | >98.00% | |
Trecovirsen sodium是一种针对HIV基因gag位点的25聚反义硫代寡核苷酸。 | ||||
| GC73412 | BDM-2 | 1643876-33-8 | >99.00% | |
BDM-2是HIV-1整合酶(IN指整合酶)的IN-LEDGF变构抑制剂(INLAI)(IC50=47 nM),具有强效的抗逆转录病毒(ARV)活性。 | ||||
| GC73486 | Atevirdine | 136816-75-6 | >98.00% | |
Atevirdine是一种强效的非核苷HIV-1逆转录酶抑制剂。 | ||||
| GC73805 | Antiviral agent 55 | 371137-60-9 | >90.00% | |
Antiviral agent 55(化合物95)是人类免疫缺陷病毒1和2 (HIV 1和HIV 2)的抑制剂,具有抗病毒活性。 | ||||
| GC73971 | Nipamovir | 2651908-78-8 | >98.00% | |
Nipamovir是一种硝基咪唑前药。 | ||||
| GC74067 | HIV-1 inhibitor-69 | 257891-65-9 | >99.00% | |
HIV-1 inhibitor-69 (compound Test set 1)是一种HIV-1 RT抑制剂。 | ||||
| GC74090 | Dimethyl fumarate-d2 | 23057-98-9 | >99.00% | |
Dimethyl fumarate-d2是氘标记的富马酸二甲酯。 | ||||
| GC74337 | IALYLQQNW | 610268-80-9 | >98.00% | |
IALYLQQNW是Epstein-Barr病毒(EBV)编码的肿瘤相关抗原潜伏膜蛋白1 (LMP1)的特异性非肽序列。 | ||||
| GC74628 | Semzuvolimab | 2409099-32-5 | >95.00% | |
Semzuvolimab是一种小鼠IgG1κ抗体,靶向p55,T细胞表面抗原T4/Leu-3(CD4)。 | ||||
| GC90488 | Tat-Beclin 1 (acetate) | - | >98.00% | |
一种诱导自噬的肽。 | ||||
